Pre-made Mavrilimumab benchmark antibody ( Whole mAb, anti-CSF2RA therapeutic antibody, Anti-GMR/CD116/CSF2R/SMDP4/CDw116GMR-alpha/GMCSFR-alpha/GM-CSF-R-alpha Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-339
Pre-Made Mavrilimumab biosimilar, Whole mAb, Anti-CSF2RA Antibody: Anti-GMR/CD116/CSF2R/SMDP4/CDw116GMR-alpha/GMCSFR-alpha/GM-CSF-R-alpha therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Mavrilimumab is a human monoclonal antibody that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R).
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Mavrilimumab biosimilar, Whole mAb, Anti-CSF2RA Antibody: Anti-GMR/CD116/CSF2R/SMDP4/CDw116GMR-alpha/GMCSFR-alpha/GM-CSF-R-alpha therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II/III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Zenyth Therapeutics Kiniksa Pharmaceuticals;MedImmune|
|Conditions Active||Giant cell arteritis;COVID-19;Inflammation|
|Conditions Discontinued||Rheumatoid arthritis|
|Development Tech||CAT Phage Display|